DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results
DBV Technologies (DBVT) provided updates on its Viaskin Peanut program and reported Q2 2024 financial results. Key highlights:
- VITESSE Phase 3 study enrollment for 4-7 year olds with peanut allergy is on track to complete by Q3 2024
- Submitted labeling proposal to FDA for COMFORT Toddlers study in 1-3 year olds
- Q2 2024 cash balance of $66.2 million, with runway extended into Q1 2025 due to cost-saving measures
- Q2 2024 net loss of $60.5 million or $0.63 per share
- Operating expenses increased to $65.0 million in H1 2024 vs $50.7 million in H1 2023, driven by R&D costs
The company faces substantial doubt about its ability to continue as a going concern beyond Q1 2025 without additional capital.
DBV Technologies (DBVT) ha fornito aggiornamenti sul suo programma Viaskin Peanut e ha riportato i risultati finanziari del secondo trimestre del 2024. Punti salienti:
- L'arruolamento nello studio VITESSE di Fase 3 per bambini di età compresa tra 4 e 7 anni con allergia al burro di arachidi è in linea per essere completato entro il terzo trimestre del 2024.
- È stata presentata una proposta di etichettatura alla FDA per lo studio COMFORT sui bambini dai 1 ai 3 anni.
- Saldo di cassa del secondo trimestre 2024 di 66,2 milioni di dollari, con una disponibilità prolungata fino al primo trimestre del 2025 grazie a misure di risparmio sui costi.
- Perdita netta del secondo trimestre 2024 di 60,5 milioni di dollari, ossia 0,63 dollari per azione.
- Le spese operative sono aumentate a 65,0 milioni di dollari nel primo semestre del 2024 rispetto ai 50,7 milioni nel primo semestre del 2023, a causa dei costi di ricerca e sviluppo.
L'azienda affronta un notevole dubbio riguardo alla propria capacità di continuare come entità economica oltre il primo trimestre del 2025 senza ulteriore capitale.
DBV Technologies (DBVT) proporcionó actualizaciones sobre su programa Viaskin Peanut y reportó los resultados financieros del segundo trimestre de 2024. Puntos destacados:
- La inscripción en el estudio VITESSE de Fase 3 para niños de 4 a 7 años con alergia al maní está en camino de completarse para el tercer trimestre de 2024.
- Se presentó una propuesta de etiquetado a la FDA para el estudio COMFORT en niños de 1 a 3 años.
- Saldo de efectivo del segundo trimestre de 2024 de 66,2 millones de dólares, con un periodo de disponibilidad extendido hasta el primer trimestre de 2025 debido a medidas de ahorro de costos.
- Pérdida neta del segundo trimestre de 2024 de 60,5 millones de dólares, o 0,63 dólares por acción.
- Los gastos operativos aumentaron a 65,0 millones de dólares en el primer semestre de 2024 frente a 50,7 millones en el primer semestre de 2023, impulsados por costos de I+D.
La empresa enfrenta serias dudas sobre su capacidad para continuar como entidad en funcionamiento más allá del primer trimestre de 2025 sin capital adicional.
DBV 테크놀로지스(DBVT)는 비아스킨 피넛 프로그램에 대한 업데이트를 제공하고 2024년 2분기 재무 결과를 보고했습니다. 주요 사항:
- 땅콩 알레르기가 있는 4-7세 어린이를 위한 VITESSE 3상 연구 등록이 2024년 3분기까지 완료될 예정입니다.
- 1-3세 아동을 위한 COMFORT 연구를 위해 FDA에 라벨링 제안을 제출했습니다.
- 2024년 2분기 현금 잔액은 6,620만 달러이며, 비용 절감 조치 덕분에 2025년 1분기까지의 자금 여력이 확보되었습니다.
- 2024년 2분기 순손실은 6,050만 달러, 즉 주당 0.63 달러입니다.
- 2024년 상반기 운영비용은 2023년 상반기 5,070만 달러에서 6,500만 달러로 증가하였으며, 이는 연구개발 비용에 의해 추진되었습니다.
회사는 2025년 1분기 이후 추가 자본 없이 계속 운영할 수 있는 능력에 대해 상당한 의구심을 갖고 있습니다.
DBV Technologies (DBVT) a fourni des mises à jour sur son programme Viaskin Peanut et a rapporté les résultats financiers du deuxième trimestre 2024. Points clés :
- L'inscription à l'étude de phase 3 VITESSE pour les enfants de 4 à 7 ans souffrant d'allergie aux arachides est sur la bonne voie pour être complétée d'ici le troisième trimestre 2024.
- Proposition d'étiquetage soumise à la FDA pour l'étude COMFORT chez les enfants de 1 à 3 ans.
- Solde de trésorerie du deuxième trimestre 2024 de 66,2 millions de dollars, avec une durée de financement prolongée jusqu'au premier trimestre 2025 grâce à des mesures de réduction des coûts.
- Perte nette du deuxième trimestre 2024 de 60,5 millions de dollars ou 0,63 dollars par action.
- Les dépenses opérationnelles ont augmenté à 65,0 millions de dollars au premier semestre 2024 contre 50,7 millions de dollars au premier semestre 2023, en raison des coûts de R&D.
L'entreprise fait face à de sérieux doutes sur sa capacité à continuer en tant qu'entité viable au-delà du premier trimestre 2025 sans capital supplémentaire.
DBV Technologies (DBVT) hat Updates zu seinem Viaskin Peanut-Programm bereitgestellt und die finanziellen Ergebnisse für das 2. Quartal 2024 gemeldet. Wichtige Höhepunkte:
- Die Rekrutierung für die VITESSE Phase 3-Studie für 4- bis 7-Jährige mit Erdnussallergie ist auf Kurs, um bis zum 3. Quartal 2024 abgeschlossen zu werden.
- Ein Etikettierungsantrag für die FDA für die COMFORT-Studie bei 1- bis 3-Jährigen wurde eingereicht.
- Der Cash-Bestand im 2. Quartal 2024 beträgt 66,2 Millionen Dollar, wobei der finanzielle Spielraum bis ins 1. Quartal 2025 aufgrund von Kostensenkungsmaßnahmen verlängert wurde.
- Der Nettoverlust im 2. Quartal 2024 beträgt 60,5 Millionen Dollar bzw. 0,63 Dollar pro Aktie.
- Die Betriebsausgaben stiegen im 1. Halbjahr 2024 auf 65,0 Millionen Dollar im Vergleich zu 50,7 Millionen Dollar im 1. Halbjahr 2023, hauptsächlich aufgrund von F&E-Kosten.
Das Unternehmen sieht sich erheblichen Zweifeln gegenüber seiner Fähigkeit, über das 1. Quartal 2025 hinaus ohne zusätzliches Kapital zu bestehen.
- VITESSE Phase 3 study enrollment is on track to complete by Q3 2024
- Submitted labeling proposal to FDA for COMFORT Toddlers study
- Cash runway extended into Q1 2025 due to cost-saving measures
- Q2 2024 net loss increased to $60.5 million from $44.8 million in Q2 2023
- Operating expenses increased by $14.3 million to $65.0 million in H1 2024
- Cash balance decreased to $66.2 million from $141.4 million at end of 2023
- Substantial doubt about ability to continue as going concern beyond Q1 2025 without additional capital
Insights
DBV Technologies' Q2 2024 financial results and program updates present a mixed picture for investors. The company's cash position has significantly decreased to
Key financial points:
- Net loss increased to
$60.5 million for H1 2024, up from$44.8 million in H1 2023. - Operating expenses rose to
$65.0 million , a28.2% increase year-over-year. - R&D expenses jumped to
$46.8 million , up38.9% from H1 2023.
The increased spending on R&D, particularly for the VITESSE Phase 3 trial, shows commitment to advancing their pipeline. However, the company's statement of "substantial doubt regarding its ability to continue as a going concern" is a red flag for investors. DBV will need to secure additional funding soon, which could lead to dilution for existing shareholders.
On a positive note, the VITESSE trial enrollment is on track, which could potentially lead to positive clinical results and increased investor interest. The company's efforts to optimize Viaskin Peanut treatment for toddlers through proposed labeling solutions show proactive engagement with the FDA.
Investors should closely monitor the company's ability to secure additional funding and the progress of its clinical trials, as these factors will be important for DBV's future prospects.
DBV Technologies' update on their Viaskin Peanut program reveals promising progress in their clinical trials, particularly for the VITESSE study. The company's focus on peanut allergy treatment in children and toddlers addresses a significant unmet medical need.
Key clinical developments:
- VITESSE Phase 3 study enrollment is on track to complete by the end of Q3 2024.
- The study involves approximately 600 subjects aged 4-7 years with peanut allergies.
- A new labeling proposal for the COMFORT Toddlers study (ages 1-3) has been submitted to the FDA.
The proposed labeling approach for the COMFORT Toddlers study is particularly intriguing. By identifying "Label-in" and "Label-out" patients based on patch wear-time experience within the first 90 days of treatment, DBV aims to optimize treatment efficacy. This personalized approach could potentially improve patient outcomes and treatment adherence.
However, it's important to note that the company is still awaiting FDA response to this proposal. The regulatory pathway for Viaskin Peanut in 1-3 year-olds remains uncertain and any delays or setbacks in FDA approval could significantly impact the company's timeline and financial position.
The ongoing dialogue with the FDA and the company's efforts to address regulatory concerns demonstrate a proactive approach to drug development. However, investors should be aware that the outcome of these discussions and the ultimate success of the Viaskin Peanut program remain uncertain at this stage.
Châtillon, France, July 30, 2024
DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results
- VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expected to be complete by end of Q3 2024
- DBV submitted a labeling proposal, informed by the EPITOPE efficacy data, to the Food and Drug Administration (FDA) to address the FDA’s protocol queries regarding patch wear-time in COMFORT Toddlers
- DBV closes Q2 2024 with a cash balance of
$66.2 million ; due to cost-saving measures, the Company’s cash runway is extended into Q1 2025
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today shared an update on the Phase 3 study, VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy), using the modified Viaskin Peanut Patch, in children ages 4 – 7 years old with peanut allergy. The Company also provided a status update on the COMFORT (Characterization of the Optimal Management of FOod allergy Relief and Treatment) Toddlers supplemental safety study in 1 – 3-year-olds with peanut allergy. DBV reported financial results for the second quarter and the first half of 2024. The quarterly and half-year financial statements were approved by the Board of Directors on July 30, 2024.
Business Update
VITESSE
DBV Technologies reports that enrollment for the VITESSE Phase 3 pivotal study in children 4 - 7-year-olds with a peanut allergy continues to be on track to screen the last subject by the end of Q3 2024. VITESSE is a trial evaluating efficacy and safety of the modified Viaskin® Peanut patch in approximately 600 subjects (randomized 2:1) with 86 participating sites in US, Canada, Europe, UK and Australia.
“We are pleased that sites in the U.S., Canada, Europe, Australia, and the UK are working hard to continue screening and enrolling subjects so that we are on-track to reach our goal of last subject into VITESSE by the end of Q3 2024,” said Pharis Mohideen, M.D. Chief Medical Officer at DBV Technologies. “We are seeing great momentum via our engagements at medical conferences and through our outreach efforts via the patient advocacy community and with study investigators. I look forward to the completion of study recruitment in the months to come.”
COMFORT Toddlers
DBV Technologies and the FDA have been engaged in ongoing dialogue since May 2023 on the COMFORT Toddlers supplemental safety study in 1 – 3-year-olds with a peanut allergy. The study protocol was submitted on November 9, 2023, with comments provided by FDA on March 11, 2024. Since March, much of the dialogue between DBV and FDA regarding the COMFORT Toddlers supplemental study has focused on patch wear-time experience, including how prescribers would advise parents and caregivers to manage day-to-day variability in patch wear time.
In this context, DBV proposed an approach, informed by the EPITOPE efficacy data, that focuses on the user experience during the first 90-days of treatment. DBV submitted to the FDA draft labeling for Section 2 – Dosing and Administration, for a potential Viaskin Peanut Prescribing Information (PI), along with comprehensive supportive data and analyses. Within the first 90-days of treatment (excluding the lead-in dosing period) it is possible to identify those patients who are very likely to have a robust clinical efficacy response based on patch wear time experience (i.e., “Label-in” patients). The proposed PI recommends continuation of treatment for these patients. With the same 90-day approach, patients less likely to have a robust clinical efficacy response, identified by their patch wear-time experience, would be identified as “Label-out” patients. In these instances, the PI would recommend a shared decision-making process, between the health care provider and the parent or caregiver, to determine whether treatment should be discontinued.
Importantly, the data shows that the “Label-in” and “Label-out” populations have similar immunological characteristics at baseline and have a similar safety profile while on treatment. However, there is clearly a difference in immune physiology (i.e., local application site sensitivity to the allergen, peanut protein) which impacts an individual patient’s wear time experience.
“DBV is and always has been dedicated to families in the food allergy community—our future patients are our top priority,” said Daniel Tasse, Chief Executive Officer of DBV Technologies. “We have offered a robust proposal to the FDA with the goal of expediting and finalizing a path forward for Viaskin Peanut in 1–3-year-olds. We believe the proposed labeling solution, which identifies patients to label-in and label-out of treatment with the Viaskin Peanut patch, will provide data-driven instructions to prescribers, and thus optimize Viaskin Peanut treatment for toddlers suffering from peanut allergy.
“On April 29th, the FDA Office of Vaccine Research and Review stated that non-COVID related backlogs were behind them, that the Division was caught-up, allowing more time for interactions with sponsors. We have indeed seen more engagement from FDA, particularly on CMC and our clinical program. DBV looks forward to continued dialogue with FDA in advancing a regulatory pathway for Viaskin Peanut in 1–3-year-olds.”
DBV is currently awaiting FDA’s response to the proposed labeling approach which was submitted on June 28th.
Conference Call
DBV will host a conference call and live audio webcast on Tuesday, July 30th, at 5:30 p.m. ET to review its second quarter 2024 financial results and provide a business update.
Participants may access this call via the below teleconferencing numbers and asking to join the DBV Technologies call:
United States: +1-877-346-6112
International: +1-848-280-6350
A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.
Financial Highlights for the second quarter Ended June 30, 2024
The Company’s interim condensed consolidated financial statements for the six months ended June 30, 2024, are prepared in accordance with accounting principles in the U.S. (“U.S. GAAP”).
Cash and Cash Equivalents
| In millions of USD (unaudited) | U.S. GAAP | IFRS | ||
| six months ended June 30, | six months ended June 30, | |||
| 2024 | 2023 | 2024 | 2023 | |
| Net cash & cash equivalents at the beginning of the period | 141.4 | 209.2 | 141.4 | 209.2 |
| Net cash flow used in operating activities | (69.8) | (46.4) | (68.7) | (45.4) |
| Net cash flow provided by / (used in) investing activities | (1.4) | (0.3) | (1.4) | (0.3) |
| Net cash flow provided by / (used in) financing activities | (0.1) | 7.8 | (1.2) | 6.8 |
| Effect of exchange rate changes on cash & cash equivalents | (3.9) | 3.7 | (3.9) | 3.7 |
| Net cash & cash equivalents at the end of the period | 66.2 | 174.0 | 66.2 | 174.0 |
Cash and cash equivalents amounted to
The Company has incurred operating losses and negative cash flows from operations since inception. As of July 30th, DBV’s available cash and cash equivalents are not projected to be sufficient to support the Company’s operating plan for at least the next 12 months. As such, there is substantial doubt regarding its ability to continue as a going concern.
Based on its current operations, plans and assumptions, the Company expects that its balance of cash and cash equivalents will be sufficient to fund its operations into Q1 2025 due to the implementation of cost-savings measures.
The Company intends to seek additional capital as it continues research and development efforts and prepares for the launch of Viaskin Peanut, if approved.
The Company cannot guarantee that it will be able to obtain the necessary financing to meet its needs or to obtain funds at attractive terms and conditions, including as a result of disruptions to the global financial markets due to any future pandemics, epidemics or global health crises and conflict in Ukraine or other global political or military crises. A severe or prolonged economic downturn could result in a variety of risks to the Company, including reduced ability to raise additional capital when needed or on acceptable terms, if at all.
If the Company is not successful in its financing objectives, the Company could have to scale back its operations, notably by delaying or reducing the scope of its research and development efforts or obtain financing through arrangements with collaborators or others that may require the Company to relinquish rights to its product candidates that the Company might otherwise seek to develop or commercialize independently.
This interim condensed financial information does not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company was unable to continue as a going concern.
Operating Income
| In millions of USD (unaudited) | U.S. GAAP | U.S. GAAP | IFRS | ||||
| six months ended June 30, | three months ended June 30, | six months ended June 30, | |||||
| 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | ||
| Research tax credits | 2.6 | 3.7 | 1.2 | 2.0 | 2.6 | 3.7 | |
| Other operating income | — | 0.7 | — | 0.3 | — | 0.8 | |
| Operating income | 2.6 | 4.5 | 1.2 | 2.3 | 2.6 | 4.5 | |
Operating income amounted to
Operating Expenses
| In millions of USD (unaudited) | U.S. GAAP | U.S. GAAP | IFRS | |||
| six months ended June 30, | three months ended June 30, | six months ended June 30, | ||||
| 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | |
| Research & Development | (46.8) | (33.7) | (25.4) | (17.6) | (46.7) | (33.6) |
| Sales & Marketing | (1.7) | (0.9) | (1.0) | (0.5) | (1.7) | (0.9) |
| General & Administrative | (16.4) | (16.1) | (8.6) | (9.2) | (16.5) | (16.2) |
| Operating expenses | (65.0) | (50.7) | (35.0) | (27.4) | (64.9) | (50.7) |
Operating expenses amounted to
Employee-related costs increased overall by
General and Administrative expenses increased slightly during the six months ended June 30, 2024, compared to the six months ended June 30, 2023, due to the optimization and rationalization of external professional services.
Net Loss and Net Loss Per Share
| U.S. GAAP | U.S. GAAP | IFRS | ||||||||
| six months ended June 30, | three months ended June 30, | six months ended June 30, | ||||||||
| 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | |||||
| Net income / (loss) (in millions of USD) | (60.5) | (44.8) | (33.1) | (24.2) | (60.6) | (44.9) | ||||
| Basic / diluted net income / (loss) per share (USD/share) | (0.63) | (0.48) | (0.34) | (0.26) | (0.63) | (0.48) | ||||
The Company recorded a net loss for the first six months ended June 30, 2024, of
On a per share basis, net loss (based on the weighted average number of shares outstanding over the period) was
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(unaudited)
| In millions of USD | U.S. GAAP | IFRS | ||
| June 30, 2024 | December 31, 2023 | June 30, 2024 | December 31, 2023 | |
| Assets | 114.2 | 183.0 | 114.2 | 183.0 |
| of which cash & cash equivalents | 66.2 | 141.4 | 66.2 | 141.4 |
| Liabilities | 35.1 | 42.8 | 35.0 | 42.7 |
| Shareholders’ equity | 79.1 | 140.2 | 79.2 | 140.3 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(unaudited)
| In millions of USD | U.S. GAAP | U.S. GAAP | IFRS | |||
| six months ended June 30, | three months ended June 30, | six months ended June 30, three months ended June 30, | ||||
| 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | |
| Revenues | 2.6 | 4.5 | 1.2 | 2.3 | 2.6 | 4.5 |
| Research & Development | (46.8) | (33.7) | (25.4) | (17.6) | (46.7) | (33.6) |
| Sales & Marketing | (1.7) | (0.9) | (1.0) | (0.5) | (1.7) | (0.9) |
| General & Administrative | (16.4) | (16.1) | (8.6) | (9.2) | (16.5) | (16.2) |
| Operating expenses | (65.0) | (50.7) | (35.0) | (27.4) | (64.9) | (50.7) |
| Financial income/(expenses) | 2.0 | 1.5 | 0.7 | 0.8 | 1.8 | 1.4 |
| Income tax | — | — | — | — | — | — |
| Net loss | (60.5) | (44.8) | (33.1) | (24.2) | (60.6) | (44.9) |
| Basic/diluted net loss per share attributable to shareholders | (0.63) | (0.48) | (0.34) | (0.26) | (0.63) | (0.48) |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
| In millions of USD | U.S. GAAP | IFRS | ||
| six months ended June 30, | six months ended June 30, | |||
| 2024 | 2023 | 2024 | 2023 | |
| Net cash flows provided / (used) in operating activities | (69.8) | (46.4) | (68.7) | (45.4) |
| Net cash flows provided / (used) in investing activities | (1.4) | (0.3) | (1.4) | (0.3) |
| Net cash flows provided / (used) in financing activities | (0.1) | 7.8 | (1.2) | 6.8 |
| Effect of exchange rate changes on cash & cash equivalents (U.S. GAAP presentation) | (3.9) | 3.7 | (3.9) | 3.7 |
| Net increase / (decrease) in cash & cash equivalents | (75.2) | (35.2) | (71.3) | (38.9) |
| Net cash & cash equivalents at the beginning of the period | 141.4 | 209.2 | 141.4 | 209.2 |
| Net cash & cash equivalents at the end of the period | 66.2 | 174.0 | 66.2 | 174.0 |
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one ordinary share) are traded on the Nasdaq Capital Select Market (Ticker: DBVT).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding DBV’s financial condition, forecast of its cash runway, the therapeutic potential of Viaskin® Peanut patch and EPIT™, designs of DBV’s anticipated clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 7, 2024, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.
Viaskin is a registered trademark and EPIT is a trademark of DBV Technologies.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
angela.marcucci@dbv-technologies.com
Attachment
FAQ
What is the status of DBV Technologies' VITESSE Phase 3 study for Viaskin Peanut?
What was DBV Technologies' (DBVT) cash balance at the end of Q2 2024?
What was DBV Technologies' (DBVT) net loss for Q2 2024?
How long does DBV Technologies (DBVT) expect its current cash to last?
